Canakinumab for anakinra-intolerant Schnitzler syndrome

Kolivras A, et al.

J Dermatol Treat · 2023

Grade Ccase reportn=1Unverified

Key Findings

  • ●Rapid improvement after first canakinumab dose
  • ●After failure of colchicine, prednisone, methotrexate, dapsone

Referenced in (1 disease)

Schnitzler Syndrome

Validation history

Full log →

No validation events recorded yet. Source will be checked on the next kipine-source-validator run.

ID: manual-a-2023-canakinumab-for-anakinraintolerant